Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06060977 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants
A Phase 1 study of Alopecia Areata (AA), sponsored by Inmagene.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 17
- Study locations
NCT06060977: Completed Phase 1 study of Alopecia Areata (AA), sponsored by Inmagene.
NCT06060977 is a Phase 1 study of Alopecia Areata (AA) that has completed, run by Inmagene. The registered enrollment target is 29 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower). The trial reports 17 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06060977, a Phase 1 study of Alopecia Areata (AA), has completed, sponsored by Inmagene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 17
- Study locations
Study Summary
The primary objective of the study is to evaluate the safety of IMG-007 in adults with Alopecia Areata.
Primary Outcome
To evaluate adverse events (AEs) emergent from multiple doses of IMG-007 in adult participants with AA.
Conditions Studied
Interventions
- DRUG IMG-007
Study Locations (17)
Ontario
- SimcoMed Health Ltd. - Barrie
- Skin Health - Cobourg
- Guelph Dermatology Research - Guelph
- Research Toronto - Toronto
Indiana
- Dawes Fretzin Clinical Resarch Group, LLC - Indianapolis
- Options Research Group - West Lafayette
Arkansas
- Northwest Arkansas Clinical Trials Center, PLLC/ Hull Dermatology P.A. - Rogers
California
- Torrance Clinical Research Institute Inc. - Lomita
Florida
- Alliance Clinical Research of Tampa - Tampa
Massachusetts
- Lahey Hospital & Medical Center - Burlington
Michigan
- Great Lakes Research Group Inc. - Bay City
Nevada
- Skin Cancer and Dermatology Institute - Reno
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2023-09-25 |
| Est. Completion | 2025-01-14 |
| Phase | Phase 1 |
What the finished NCT06060977 record still lists
NCT06060977 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Alopecia Areata (AA) appearing as the primary indexed condition, and to 1 intervention - of which IMG-007 is the first listed.
NCT06060977 lists 17 locations in 13 states (Ontario, Indiana, Arkansas).
Frequently Asked Questions
What is clinical trial NCT06060977 about?
NCT06060977 is a clinical study titled "A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants". The primary objective of the study is to evaluate the safety of IMG-007 in adults with Alopecia Areata.
What is the current status of trial NCT06060977?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2023-09-25. Estimated completion is 2025-01-14.
What conditions does trial NCT06060977 study?
This clinical trial studies the following conditions: Alopecia Areata (AA).
What interventions are being tested in trial NCT06060977?
The interventions under investigation include: IMG-007 (DRUG).
Who is sponsoring clinical trial NCT06060977?
This trial is sponsored by Inmagene, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06060977 being conducted?
This trial has 17 study locations across Arkansas, California, Florida, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia Areata (AA)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06060977's enrollment target sits among peer trials
29 1440th of 2000 higher than 554 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI